-
市场
-
产品
-
资讯
-
Moo社区
-
课堂
-
查看更多
-
功能介绍
-
费用费用透明，无最低余额限制
投资选择、功能介绍、费用相关信息由Moomoo Financial Inc.提供
- English
- 中文繁體
- 中文简体
- 深色
- 浅色
Short Interest in Avalo Therapeutics, Inc. (NASDAQ:AVTX) Decreases By 27.5%
Short Interest in Avalo Therapeutics, Inc. (NASDAQ:AVTX) Decreases By 27.5%
Avalo Therapeutics, Inc. (NASDAQ:AVTX – Get Rating) saw a significant decline in short interest during the month of October. As of October 31st, there was short interest totalling 35,300 shares, a decline of 27.5% from the October 15th total of 48,700 shares. Based on an average daily volume of 31,100 shares, the short-interest ratio is presently 1.1 days. Currently, 0.4% of the company's stock are sold short.
Avalo Therapeutics Trading Down 0.5 %
NASDAQ AVTX traded down $0.03 during trading on Monday, hitting $5.77. The company's stock had a trading volume of 6,065 shares, compared to its average volume of 41,556. The company has a debt-to-equity ratio of 5.23, a current ratio of 1.07 and a quick ratio of 0.97. The business's 50 day simple moving average is $4.92 and its 200-day simple moving average is $5.19. Avalo Therapeutics has a fifty-two week low of $2.42 and a fifty-two week high of $27.84.
Get Avalo Therapeutics alerts:Analysts Set New Price Targets
Separately, Oppenheimer lowered their price target on Avalo Therapeutics from $17.00 to $10.00 in a report on Wednesday, November 9th.
Institutional Investors Weigh In On Avalo Therapeutics
Institutional investors have recently added to or reduced their stakes in the business. Millennium Management LLC acquired a new stake in Avalo Therapeutics in the second quarter worth about $506,000. Goldman Sachs Group Inc. lifted its holdings in shares of Avalo Therapeutics by 23.8% during the second quarter. Goldman Sachs Group Inc. now owns 649,653 shares of the company's stock worth $324,000 after purchasing an additional 124,769 shares during the period. Renaissance Technologies LLC lifted its holdings in shares of Avalo Therapeutics by 819.1% during the first quarter. Renaissance Technologies LLC now owns 367,193 shares of the company's stock worth $266,000 after purchasing an additional 327,241 shares during the period. Assenagon Asset Management S.A. acquired a new stake in shares of Avalo Therapeutics during the third quarter worth about $52,000. Finally, Leo Brokerage LLC acquired a new stake in shares of Avalo Therapeutics during the first quarter worth about $45,000.About Avalo Therapeutics
(Get Rating)
Avalo Therapeutics, Inc, a clinical-stage precision medicine company, discovers, develops, and commercializes targeted therapeutics for patients with unmet clinical need in immunology, immuno-oncology, and rare genetic diseases. It develops AVTX-002, a fully human anti-LIGHT monoclonal antibody, which is under Phase II clinical trial for the treatment of non-eosinophilic asthma, as well as inflammatory bowel disease, including moderate to severe Crohn's disease, and ulcerative colitis; and Phase III clinical trial for the treatment of COVID-19 acute respiratory distress syndrome.
Recommended Stories
- Get a free copy of the StockNews.com research report on Avalo Therapeutics (AVTX)
- Is It Time To Take A Ride With Joby Aviation's EV Innovations?
- After a $100 Haircut, is Catalent an Oversold Pharma Play?
- Is Tyson Foods Too Cheap To Ignore?
- Alphabet Stock Offers a Rare Buying Opportunity
- Solar Battery Maker Enphase Clears Buy Point: Can Rally Hold?
Receive News & Ratings for Avalo Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Avalo Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
Avalo Therapeutics, Inc. (NASDAQ:AVTX – Get Rating) saw a significant decline in short interest during the month of October. As of October 31st, there was short interest totalling 35,300 shares, a decline of 27.5% from the October 15th total of 48,700 shares. Based on an average daily volume of 31,100 shares, the short-interest ratio is presently 1.1 days. Currently, 0.4% of the company's stock are sold short.
阿瓦洛治疗公司(纳斯达克代码：AVTX-GET评级)在10月份看到空头股数的销售额大幅下降。截至10月31日，空头股数共有35,300股，较10月15日的48,700股下降了27.5%。以日均成交量31,100股计算，目前短息比率为1.1天。目前，该公司0.4%的股票被卖空。
Avalo Therapeutics Trading Down 0.5 %
Avalo治疗公司股价下跌0.5%
NASDAQ AVTX traded down $0.03 during trading on Monday, hitting $5.77. The company's stock had a trading volume of 6,065 shares, compared to its average volume of 41,556. The company has a debt-to-equity ratio of 5.23, a current ratio of 1.07 and a quick ratio of 0.97. The business's 50 day simple moving average is $4.92 and its 200-day simple moving average is $5.19. Avalo Therapeutics has a fifty-two week low of $2.42 and a fifty-two week high of $27.84.
在周一的交易中，纳斯达克AVTX股价下跌0.03美元，至5.77美元。该公司股票的成交量为6,065股，而其平均成交量为41,556股。该公司的债务权益比为5.23，流动比率为1.07，速动比率为0.97。该业务的50日简单移动均线切入位为4.92美元，200日简单移动均线切入位为5.19美元。Avalo Treateutics的股价为52周低点2.42美元，52周高点27.84美元。
Analysts Set New Price Targets
分析师设定新的价格目标
Separately, Oppenheimer lowered their price target on Avalo Therapeutics from $17.00 to $10.00 in a report on Wednesday, November 9th.
另外，奥本海默在11月9日星期三的一份报告中将Avalo治疗公司的目标价从17.00美元下调至10.00美元。
Institutional Investors Weigh In On Avalo Therapeutics
机构投资者看好Avalo治疗公司
About Avalo Therapeutics
关于Avalo Treateutics
(Get Rating)
(获取评级)
Avalo Therapeutics, Inc, a clinical-stage precision medicine company, discovers, develops, and commercializes targeted therapeutics for patients with unmet clinical need in immunology, immuno-oncology, and rare genetic diseases. It develops AVTX-002, a fully human anti-LIGHT monoclonal antibody, which is under Phase II clinical trial for the treatment of non-eosinophilic asthma, as well as inflammatory bowel disease, including moderate to severe Crohn's disease, and ulcerative colitis; and Phase III clinical trial for the treatment of COVID-19 acute respiratory distress syndrome.
Avalo Treateutics，Inc.是一家临床阶段的精密药物公司，为免疫学、免疫肿瘤学和罕见遗传病方面未得到满足的临床需求的患者发现、开发和商业化靶向疗法。该公司开发了AVTX-002，这是一种完全人类抗光的单抗，正在进行第二阶段临床试验，用于治疗非嗜酸性哮喘以及炎症性肠道疾病，包括中到重度克罗恩病和溃疡性结肠炎；以及第三阶段临床试验，用于治疗新冠肺炎急性呼吸窘迫综合征。
Recommended Stories
推荐故事
- Get a free copy of the StockNews.com research report on Avalo Therapeutics (AVTX)
- Is It Time To Take A Ride With Joby Aviation's EV Innovations?
- After a $100 Haircut, is Catalent an Oversold Pharma Play?
- Is Tyson Foods Too Cheap To Ignore?
- Alphabet Stock Offers a Rare Buying Opportunity
- Solar Battery Maker Enphase Clears Buy Point: Can Rally Hold?
- 免费获取StockNews.com关于Avalo治疗公司(AVTX)的研究报告
- 是时候与Joby Aviation的电动汽车创新一起兜风了吗？
- 在100美元的理发之后，Catalent是一个超卖的制药公司吗？
- 泰森食品是不是太便宜了，不容忽视？
- Alphabet股票提供难得的买入机会
- 太阳能电池制造商安相清理买入点位：涨势能否守住？
Receive News & Ratings for Avalo Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Avalo Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
接受《阿瓦洛治疗日报》的新闻和评级-在下面输入您的电子邮件地址，通过MarketBeat.com的免费每日电子邮件时事通讯接收对Avalo治疗公司和相关公司的最新新闻和分析师评级的每日简要摘要。
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国，moomoo上的投资产品和服务由Moomoo Financial Inc.提供，一家受美国证券交易委员会（SEC）监管的持牌主体。 Moomoo Financial Inc.是金融业监管局（FINRA）和证券投资者保护公司（SIPC）的成员。
在新加坡，moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供，该公司受新加坡金融管理局（MAS）监管(牌照号码︰CMS101000) ，持有资本市场服务牌照 (CMS) ，持有财务顾问豁免（Exempt Financial Adviser）资质。本内容未经新加坡金融管理局的审查。
在澳大利亚，moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供，该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构（AFSL No. 224663）。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件，这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大，通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供，并受加拿大投资监管机构（CIRO）监管。
在马来西亚，moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供，该公司受马来西亚证券监督委员会（SC）监管(牌照号码︰eCMSL/A0397/2024) ，持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
风险及免责提示
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国，moomoo上的投资产品和服务由Moomoo Financial Inc.提供，一家受美国证券交易委员会（SEC）监管的持牌主体。 Moomoo Financial Inc.是金融业监管局（FINRA）和证券投资者保护公司（SIPC）的成员。
在新加坡，moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供，该公司受新加坡金融管理局（MAS）监管(牌照号码︰CMS101000) ，持有资本市场服务牌照 (CMS) ，持有财务顾问豁免（Exempt Financial Adviser）资质。本内容未经新加坡金融管理局的审查。
在澳大利亚，moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供，该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构（AFSL No. 224663）。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件，这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大，通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供，并受加拿大投资监管机构（CIRO）监管。
在马来西亚，moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供，该公司受马来西亚证券监督委员会（SC）监管(牌照号码︰eCMSL/A0397/2024) ，持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用浏览器的分享功能，分享给你的好友吧